The extracellular matrix (ECM) is a complex meshwork of proteins that provides structural and biochemical support to cells. We have recently reported that the homozygous ablation of Sned1, which encodes the novel ECM protein SNED1, caused neonatal lethality, and the few knockout (KO) survivors we obtained exhibited craniofacial malformations including shorter snouts and wider neurocrania (Figure 1). Since cranial neural crest cells (NCCs) form the facial skeleton and given the importance of the ECM in guiding NCC phenotype, we hypothesized that SNED1 influences the behavior of this cell population. To test this, we generated an NCC-specific Sned1 KO mouse. While Sned1NCC-/NCC- mice survive, they present craniofacial anomalies resembling the malformations observed in the global Sned1 KOmice (Barqué et al., Dev Dyn, 2020). In order to form craniofacial structures, cephalic NCCs first need to delaminate from the neural tube, then migrate towards the frontonasal region and the pharyngeal arches, and there differentiate into bone and cartilage. Our goal is now to determine precisely which cellular processes along the NCC path are directly controlled by SNED1. To assess this, we are first performing in-vivo assays including in-situ hybridization and immunohistochemical staining on Sned1NCC-/NCC- and control mouse embryos at different embryonic timepoints to assess NCC behaviors. In parallel, we are conducting in-vitro assays using neural tube explants excised from Sned1NCC-/NCC- and control mouse embryos and recapitulating the key steps NCCs take towards the formation of craniofacial structures. These steps include migration, proliferation, and chondrogenic and osteogenic differentiation and can be monitored by tracking the expression of specific molecular markers. Once we identify which cellular processes are controlled by SNED1, we will turn our focus to the identification of the molecular mechanisms by which SNED1 governs NCC phenotype and craniofacial morphogenesis. Sequence analysis of SNED1 revealed two consensus binding sites for integrins, which are known ECM receptors. Thus, we have developed SNED1 constructs containing mutations in the putative integrin-binding sites that we will use to elucidate whether integrins serve as SNED1 receptors. Importantly, deletion of 2q37.3, a region that comprises the SNED1 locus, has been linked to facial dysmorphism in patients. We thus propose that SNED1 contributes to the phenotype of these patients and that our novel mouse model may shed light on some of the features of this syndrome. Moreover, we previously reported SNED1 as a promoter of breast cancer metastasis (Naba et al., eLife, 2014). Since metastatic cells share common features with NCC, our studies will also allow us to better understand the role of SNED1 in metastasis.
Read full abstract